Be The Match BioTherapies & NantKwest Announce Collaboration to Accelerate Development of Cell Therapy to Prevent COVID-19 De...
19 5월 2020 - 9:00PM
Business Wire
Be The Match BioTherapies will provide
allogeneic cellular source material to NantKwest for clinical trial
addressing primary cause of COVID-19 fatality
Be The Match BioTherapies®, an organization offering solutions
for companies developing and commercializing cell and gene
therapies, and NantKwest (Nasdaq: NK), a next generation,
clinical-stage immunotherapy company focused on harnessing the
unique power of the immune system using natural killer (NK) cells
to treat cancer and infectious diseases, today announced an
agreement through which Be The Match BioTherapies is providing
donor material for a NantKwest Phase 1b clinical trial to address
acute respiratory distress syndrome (ARDS), one of the primary
causes of COVID-19 deaths.
The agreement combines Be The Match BioTherapies’ ability to
provide high-quality cellular source material from the world’s
largest registry of volunteer donors with NantKwest’s capabilities
in manufacturing off-the-shelf cell therapies. NantKwest’s
allogeneic cell therapy is derived from human bone marrow and
designed to treat the ARDS that results from severe COVID-19 cases.
The therapy, called BM-Allo.MSC, uses mesenchymal stem cells
(MSCs), multipotent progenitor cells known to have immunomodulatory
properties, to reduce the lung inflammation associated with ARDS.
Similar work in Europe with allogeneic MSC products in patients
with COVID-19 and ARDS has demonstrated safety and efficacy in
reducing inflammatory processes.
NantKwest recently announced FDA authorization of its
investigational new drug (IND) application for BM-Allo.MSC and is
moving rapidly to initiate a Phase 1b trial in patients with severe
COVID-19. To expedite trial initiation, Be The Match BioTherapies
is providing cryopreserved donor stem cell material from the Be The
Match BioBank, a program of the National Marrow Donor Program®/Be
The Match®. The accelerated access to material, combined with
NantKwest’s scalable manufacturing processes, will allow for rapid
distribution of BM-Allo.MSC to patients in need.
“There is an immediate need for COVID-19 therapies across all
stages of the disease, including for patients with ARDS, which is
one of the most critical conditions caused by COVID-19,” said
Patrick Soon-Shiong, MD, Chairman and Chief Executive Officer of
NantKwest. “Thanks to the quality source material provided by Be
The Match BioTherapies, we are prepared to rapidly scale
manufacturing of this much-needed therapy, potentially saving
numerous patients’ lives.”
“Through our team’s unparalleled ability to identify, source and
deliver high-quality donor material we have the opportunity to
support the advancement of a cell therapy with potential to change
the world. We are proud to partner with NantKwest to support our
mission to save lives through cellular therapy and continue to make
a difference for critically ill patients around the globe,” said
Chris McClain, Senior Vice President, Sales and New Business
Development at Be The Match BioTherapies.
About Be The Match BioTherapies
Be The Match BioTherapies is the only cell and gene therapy
solutions provider with customizable services to support the
end-to-end cell therapy supply chain. Backed by the
industry-leading experience of the National Marrow Donor Program
(NMDP)®/Be The Match®, and a research partnership with the CIBMTR®
(Center for International Blood and Marrow Transplant Research®),
the organization designs solutions that advance the development of
cell and gene therapies across the globe.
Be The Match BioTherapies is dedicated to accelerating patient
access to life-saving cell and gene therapies by providing
high-quality cellular source material from the Be The Match
Registry®, the world’s largest and most diverse registry of more
than 22 million potential blood stem cell donors. Through
established relationships with apheresis, marrow collection and
transplant centers worldwide, the organization develops, onboards,
trains and manages expansive collection networks to advance cell
therapies. Be The Match BioTherapies uses proven infrastructure
consisting of regulatory compliance and managed logistics experts,
as well as cell therapy supply chain case managers to successfully
transport and deliver regulatory compliant life-saving therapies
across the globe. Through the CIBMTR, Be The Match BioTherapies
extends services beyond the cell therapy supply chain to include
long-term follow-up tracking for the first two FDA-approved CAR-T
therapies.
For more information, visit www.BeTheMatchBioTherapies.com or
follow Be The Match BioTherapies on LinkedIn or Twitter at
@BTMBioTherapies.
About NantKwest
NantKwest (Nasdaq: NK) is an innovative, clinical-stage
immunotherapy company focused on harnessing the power of the innate
immune system to treat cancer and virally-induced infectious
diseases. NantKwest is the leading producer of clinical dose forms
of off-the-shelf natural killer (NK) cell therapies. The activated
NK cell platform is designed to destroy cancer and virally-infected
cells. The safety of these optimized, activated NK cells—as well as
their activity against a broad range of cancers—has been tested in
Phase I clinical trials in Canada and Europe, as well as in
multiple Phase I and II clinical trials in the United States. By
leveraging an integrated and extensive genomics and transcriptomics
discovery and development engine, together with a pipeline of
multiple, clinical-stage, immuno-oncology programs, NantKwest’s
goal is to transform medicine by delivering living drugs-in-a-bag
and bringing novel NK cell-based therapies to routine clinical
care. NantKwest is a member of the NantWorks ecosystem of
companies. For more information, please visit
www.nantkwest.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200519005211/en/
Ten Bridge Communications Gwendolyn Schanker, (269)-921-3607
gwen@tenbridgecommunications.com
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
NantKwest (NASDAQ:NK)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024